GlassScriptPhysician profile
Kathleen Sharkey
NPI 1679760086
$8,273.32
in general payments reported to CMS, 2019-2025
60 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $1,613 · 2023: $2,548 · 2024: $1,363 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,575 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,574.50 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $898.02 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $838.69 | 2021-2025 | |
| Janssen Biotech, INC. | $760.29 | 2022-2025 | Darzalex, Tecvayli, Erleada |
| Abbvie INC. | $597.54 | 2021-2025 | |
| Incyte Corporation | $541.47 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $334.66 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $299.60 | 2021-2025 | Tagrisso, Enhertu, Farxiga |
| Genzyme Corporation | $292.54 | 2021-2024 | |
| Pfizer INC. | $270.77 | 2021-2025 | |
| Seagen INC. | $255.49 | 2021-2023 | Adcetris, Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $229.78 | 2021-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $186.32 | 2021-2024 | Padcev, Xtandi |
| Gilead Sciences, INC. | $181.91 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $160.40 | 2021-2025 | Zejula, Jemperli |
| Sobi, INC | $159.73 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $152.47 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $152.04 | 2022-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $123.62 | 2021-2023 | |
| Puma Biotechnology, INC. | $123.54 | 2021-2024 | |
| Array Biopharma INC | $121.71 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Lilly USA, LLC | $101.01 | 2023 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $100.62 | 2021-2023 | Vectibix, Nplate, Xgeva |
| Ipsen Biopharmaceuticals, INC | $93.88 | 2022-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $91.55 | 2023-2025 | Zoladex |
| Servier Pharmaceuticals LLC | $78.01 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $73.47 | 2024-2025 | Monoferric, Cosela |
| Novo Nordisk INC | $69.05 | 2021-2022 | |
| Dova Pharmaceuticals | $66.03 | 2021 | |
| Mirati Therapeutics, INC. | $64.77 | 2023-2024 | Krazati |
| Beigene USA, INC. | $53.39 | 2023-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $46.14 | 2023-2025 | Fruzaqla, Cuvitru |
| Stemline Therapeutics INC. | $45.92 | 2023-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $42.31 | 2023-2025 | Xpovio |
| Dendreon Pharmaceuticals LLC | $41.06 | 2021-2025 | Provenge |
| Taiho Oncology, INC. | $37.01 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $36.58 | 2023 | Libtayo |
| Eisai INC. | $35.15 | 2021 | |
| Genentech USA, INC. | $33.54 | 2021 | |
| Kyowa Kirin, INC. | $33.35 | 2021-2022 | |
| Tolmar, INC. | $31.22 | 2024-2025 | Eligard, Rubraca |
| Adaptive Biotechnologies Corporation | $30.50 | 2023 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $29.72 | 2025 | |
| Daiichi Sankyo INC. | $28.96 | 2021-2023 | Enhertu |
| Alnylam Pharmaceuticals INC. | $26.52 | 2023 | Givlaari |
| Legend Biotech USA INC. | $26.05 | 2024 | |
| Adc Therapeutics America, INC. | $24.95 | 2025 | |
| Geron Corporation | $24.16 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $23.33 | 2024 | Sylvant |
| Exact Sciences Corporation | $21.88 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $21.24 | 2025 | Auvelity |
| Global Blood Therapeutics, INC. | $20.16 | 2021 | |
| Genmab U.S., INC. | $17.53 | 2025 | Epkinly |
| Springworks Therapeutics, INC. | $17.19 | 2025 | Ogsiveo |
| Heron Therapeutics, INC. | $16.98 | 2022 | |
| Neuronetics, INC. | $16.38 | 2025 | Neurostar Tms Therapy System |
| Pharmaand Gmbh | $16.06 | 2025 | Rubraca |
| Foundation Medicine, INC. | $14.79 | 2023 | |
| Clovis Oncology, INC. | $14.48 | 2021 | |
| Exelixis INC. | $14.13 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $13.66 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Sharkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.